The Claim
In Japanese adults with type 1 diabetes using sensor-augmented pump therapy, a personalized kinetic model for HbA1c (cHbA1c) demonstrates no average bias compared to laboratory-measured HbA1c, while estimated HbA1c (eHbA1c) and glucose management indicator (GMI) show clinically significant negative biases of −0.4% and −0.3%, respectively.
What the research says
Not yet evaluated
We are still looking at what the research says.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A new way to estimate blood sugar levels (called cHbA1c) is more accurate than two older methods (eHbA1c and GMI) in Japanese adults with type 1 diabetes who use insulin pumps and glucose sensors — the older methods tend to underestimate blood sugar levels by a noticeable amount.
See the scientific wording
A personalized kinetic model for HbA1c (cHbA1c) shows no average bias relative to laboratory HbA1c, whereas estimated HbA1c (eHbA1c) and glucose management indicator (GMI) exhibit clinically significant negative biases of −0.4% and −0.3%, respectively, in Japanese adults with type 1 diabetes using sensor-augmented pump therapy.
What the research says
1 studyThe study tested a new way to estimate HbA1c using personalized data and found it matched lab results much better than older methods, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.